A Potential New Target for ALS Therapies
The Context: Mutations in a gene called NEK1 are known to cause ALS in a subset of patients, but how exactly these mutations affect motor neurons...
The Context: Mutations in a gene called NEK1 are known to cause ALS in a subset of patients, but how exactly these mutations affect motor neurons...
The Context: ALS is a disease that manifests differently in each patient, with some cases resulting from genetic predispositions, and others sporadically. Because the causes can...
The Context: Turning patient stem cells into the different cell types of the brain offers immense promise for studying and treating neurodegenerative diseases such as Alzheimer’s,...
Alzheimer’s, Parkinson’s, multiple sclerosis, cancer: they’re all diseases that are, to this day, largely a mystery, and treatment options are scarce. But thanks to stem cells,...
The Context: Neuromuscular disorders such as ALS arise from degeneration of brain cells that send signals to the muscles, and there are no treatments that address...
Ezogabine (an epilepsy drug), has successfully reduced a hallmark of ALS in 65 patients participating in a phase 2 clinical trial, according to a recent report...
The Context: Amyotrophic lateral sclerosis (ALS) affects motor neurons, the cells that send signals to our muscles, gradually paralyzing patients. Scientists know that a mutation in...
An epilepsy drug, initially tested using a stem cell model of ALS developed with NYSCF support, has successfully reduced motor neuron excitability (a hallmark of the...
The National Institute of Neurological Disorders and Stroke (NINDS) have awarded a 3.7 million dollar Small Business Innovation Research (SBIR) Fast-Track grant to a biotech company...
Over the past 20 years, embryonic stem cell (ESC) research has evolved from a brand new field with lots of promise to one that is actively...
New research from the lab of NYSCF — Robertson Investigator Justin Ichida, PhD, at the University of Southern California suggests that a faulty gene can cause...
NYSCF welcomed six of the most talented stem cell researchers and neuroscientists from around the world into the NYSCF Investigator Program and the NYSCF Innovator Community....
The National Stem Cell Foundation (NSCF) and the NYSCF Research Institute announced that a grant from NSCF will be used to fund NYSCF research on cell...
The NYSCF Research Institute announced a new collaboration with Yumanity Therapeutics, a company focused on transforming drug discovery for diseases caused by protein misfiling, to generate...
NYSCF does not treat patients with stem cell therapies. Please visit www.clinicaltrials.gov for a complete listing of clinical trials being conducted worldwide, or consult your physician. Stem cell research...
The MacArthur Foundation named Dr. Lorenz Studer a 2015 MacArthur Fellow. A Founding member of NYSCF’s Medical Advisory Board, Dr. Studer served on inaugural juries of...
Researchers at the Harvard Stem Cell Institute, led by NYSCF Chief Scientific Officer Dr. Kevin Eggan, discovered a new, promising treatment for ALS, or Lou Gehrig’s...
NYSCF – Robertson Stem Cell Investigator Dr. Paola Arlotta, of Harvard University, published her latest work on gene co-regulation in Nature Neuroscience. The regulatory logic, or...